Cellares and GenomeFrontier to assess automated GF-CART01 production
Cellares and GenomeFrontier Therapeutics have announced a collaboration to assess automated manufacturing for the latter’s investigational CAR-T cell therapy, GF-CART01,…
All articles by Salong Debbarma
Salong Debbarma
-
-
Viatris’ Wakix receives Japanese approval to treat OSAS and narcolepsy
Japan’s Ministry of Health, Labour and Welfare has approved Viatris’ Wakix (pitolisant) for excessive daytime sleepiness (EDS) related to obstructive…
-
Gilead and PAHO agree to expedite lenacapavir access for HIV prevention
Gilead Sciences and the Pan American Health Organization (PAHO) have signed an agreement to expedite access to the company’s twice-yearly…
-
Eli Lilly and QurCan sign genetic medicine deal
Eli Lilly and Company and QurCan Therapeutics have signed an exclusive research and collaboration agreement to develop genetic medicine therapeutics…
-
Cheplapharm to take over 20 medicines and three sites from Sanofi
Cheplapharm has entered a strategic partnership to take over a portfolio of 20 mature medicines, along with three manufacturing facilities…
-
FDA reduces monitoring time for Amgen’s Imdelltra infusions
The US Food and Drug Administration (FDA) has approved an update to the prescribing information for Amgen’s Imdelltra (tarlatamab-dlle), reducing…
-
Exegenesis Bio and Modalis sign research deal for Duchenne therapy
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for…
-
ABEC to expand global manufacturing network with new Wilson facility
ABEC is set to open a new manufacturing facility in Wilson, North Carolina, US, expanding its network for biopharmaceutical process…
-
Solstice Oncology secures $225m to drive porustobart’s development for cancer
Harbour BioMed’s partner Solstice Oncology has raised $225m in funding to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy.…
-
TwoStep Therapeutics raises $62.5m in funding to advance TS-104
TwoStep Therapeutics has raised $62.5m in an oversubscribed Series A financing round to support its lead peptide-drug conjugate, TS-104, for…